Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody

Summary

The investigators conduct a single-arm, single-center, prospective clinical study enrolling patients diagnoses with pMMR / MSS type middle and low locally advanced rectal cancer who had not received systemic anti-tumor therapy to explore the efficacy and safety of short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody as neoadjuvant therapy.

Timeline

Start

2023-09-01

Primary completion

2028-12-31

Completion

2029-12-31

Drugs

Indications